Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock Has Consensus Target Price of $2.80

Aprea Therapeutics, Inc. (NASDAQ:APRE) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $2.80.

APRE has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. LADENBURG THALM/SH SH initiated coverage on Aprea Therapeutics in a research report on Wednesday. They issued a “buy” rating and a $2.00 price objective for the company. Finally, Wedbush reduced their price target on shares of Aprea Therapeutics to $3.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Aprea Therapeutics stock. AIGH Capital Management LLC raised its stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) by 174.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,015,541 shares of the company’s stock after acquiring an additional 645,000 shares during the quarter. AIGH Capital Management LLC owned approximately 8.47% of Aprea Therapeutics worth $775,000 at the end of the most recent quarter. 34.19% of the stock is currently owned by institutional investors.

Aprea Therapeutics Price Performance

Shares of APRE stock traded up $0.00 during midday trading on Wednesday, hitting $0.60. The company had a trading volume of 14,425 shares, compared to its average volume of 878,766. The stock has a market cap of $7.60 million, a price-to-earnings ratio of -0.56 and a beta of 1.66. The company’s 50 day simple moving average is $0.73 and its 200 day simple moving average is $0.77. Aprea Therapeutics has a 52-week low of $0.55 and a 52-week high of $1.69.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.11. Analysts anticipate that Aprea Therapeutics will post -0.34 EPS for the current year.

About Aprea Therapeutics

Aprea Therapeutics, Inc (NASDAQ: APRE) is a clinical-stage biopharmaceutical company developing targeted therapies for cancer. Its research focuses on treatments designed to exploit weaknesses in tumor cells, with an emphasis on DNA damage response and cell-cycle regulation.

The company’s lead investigational program is ATRN-119, an oral, selective inhibitor of ataxia telangiectasia and Rad3-related protein, or ATR. ATRN-119 is being evaluated in early-stage clinical studies for patients with advanced solid tumors.